> Clinical results
Sensibio AR contains patented technology ROSACTIV® (patent n°FR2885301B1) which significantly inhibits the secretion of VEGF by keratinocytes (-75%**)(1) leading to the reduction of vasodilation responsible of redness.
After 28 days of use of Sensibio AR twice daily in patients with sensitive skin, Sensibio AR significantly reduces:
- telangiectasias by 37.2%** (2)
- erythrosis by 34%** (2)
- flushes by 35%** (2)
- feeling of tightness by 44.4%* (2)
- number of redness of 5.5%* (2)
- scorage of quality-of-life DLQI of 60%** meaning a positive improvement in quality of life (2)
After 56 days of use, Sensibio AR significantly reduces:
- telangiectasias by 41.9%** (2)
- erythrosis by 34%** (2)
- flushes by 43.3%*** (2)
- feeling of tightness by 51.9%* (3)
- number of redness by 8.3%* (2)
- scorage of quality-of-life DLQI of 76%** meaning a positive improvement in quality of life (2)
- Sensibio AR is also a very good moisturizer with 35.8%* of hydration after 8h of use (4)
Tolerance
Tolerance is very high on sensitive/reactive skin with redness or cold sensitive and couperosis (1, 2, 5, 6)
*p<0.05, Student t.test **p<0.001, Student test
> Patients feedbacks
After 21 days of use, for more than 90% of subjects, sensations of discomfort are reduced, skin is soothed and less reactive (6). For more than 77% of subjects, Sensibio AR prevents and reduce redness (5).
(1) In vitro tests. Activity of Rosactiv® patent on the secretion of VEGF by normal human keratinocytes stimulated by TNF-α
(2) Evaluation of cutaneous tolerance and efficacy on 37 subjects aged from 19 to 65 years old with sensitive skin that reddens easily with or without telangiectasia after twice daily application of Sensibio AR for 28 days or 56 days by clinical scorage of telangiectasia, erythrosis, flushes, feeling of tightness, measurement of redness by VISIA and by self-assessment of DLQI (Dermatology Life Quality Index) and clinical examination of product acceptability.
(3) Evaluation of efficacy on redness 30 volunteers aged from 23 to 65 years old with dry, sensitive skin that reacts to the cold by measuring a parameter with chromameter after 28 days of twice daily use of Sensibio AR.
(4) Measurement of hydration level by corneometry on 10 subjects aged from 33 to 64 years old with dry or moderately hydrated skin after 8h of use of Sensibio AR. France
(5) Self-assessment of cutaneous and ocular tolerance and efficacy (% satisfaction) on 22 subjects aged from 32 to 70 years old with sensitive/reactive skin and redness after 21 days of twice daily use of Sensibio AR.
(6) Self-assessment of tolerance and efficacy (% satisfaction) on 30 volunteers aged from 23 to 65 years old with dry, sensitive skin that reacts to the cold after 28 days of twice daily use of Sensibio AR.
